Literature DB >> 21042169

Association of high-density lipoprotein cholesterol with coronary heart disease risk across categories of low-density lipoprotein cholesterol: the atherosclerosis risk in communities study.

Paul Muntner1, Fleur Lee, Brad C Astor.   

Abstract

INTRODUCTION: National cholesterol treatment guidelines include a low level of high-density lipoprotein (HDL) cholesterol (<40 mg/dL) as a major risk factor for coronary heart disease (CHD) that should be considered when making decisions on treatment of low-density lipoprotein (LDL) cholesterol.
METHODS: We investigated the association of HDL and LDL-cholesterol with incident CHD events (fatal or nonfatal CHD) over 14 years of follow-up among 13,615 adults aged 45 to 64 years in the Atherosclerosis Risk in Communities study.
RESULTS: A total of 966 (7.1%) participants had a CHD event during follow-up. After adjustment for age, race, sex, diabetes, smoking, alcohol consumption, systolic blood pressure, waist circumference, chronic kidney disease and physical activity, a graded association was present between progressively lower levels of HDL-cholesterol and higher CHD risk, overall (P < 0.001) and within each level of LDL-cholesterol (<100, 100-129, 130-159, 160-189 and ≥190 mg/dL) investigated (all P < 0.05). In addition, after multivariable adjustment including LDL-cholesterol, each standard deviation higher HDL-cholesterol (18 mg/dL) was associated with a hazard ratio of incident CHD of 0.70 (95% CI: 0.63-0.77).
CONCLUSIONS: These data suggest a graded association exists between lower levels of HDL-cholesterol and CHD across the full range of LDL-cholesterol levels. As interventions targeting HDL levels are developed, the combinatorial effects of lower HDL levels with various levels of LDL-cholesterol should be examined.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21042169     DOI: 10.1097/MAJ.0b013e3181f97e4a

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  6 in total

1.  Dysmetabolic Signals in "Metabolically Healthy" Obesity.

Authors:  Peter Manu; Constantin Ionescu-Tirgoviste; James Tsang; Barbara A Napolitano; Martin L Lesser; Christoph U Correll
Journal:  Obes Res Clin Pract       Date:  2012-01       Impact factor: 2.288

Review 2.  The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotype.

Authors:  John D Brunzell; Alberto Zambon; Samir S Deeb
Journal:  Biochim Biophys Acta       Date:  2011-09-25

3.  The C-565T Polymorphism (rs2422493) of the ATP-binding Cassette Transporter A1 Gene Contributes to the Development and Severity of Coronary Artery Disease in an Iranian Population.

Authors:  Khalil Mahmoodi; Koorosh Kamali; Habib Ghaznavi; Mohammad Soleiman Soltanpour
Journal:  Oman Med J       Date:  2018-07

4.  Segregation of LIPG, CETP, and GALNT2 mutations in Caucasian families with extremely high HDL cholesterol.

Authors:  Ian Tietjen; G Kees Hovingh; Roshni R Singaraja; Chris Radomski; Amina Barhdadi; Jason McEwen; Elden Chan; Maryanne Mattice; Annick Legendre; Patrick L Franchini; Marie-Pierre Dubé; John J P Kastelein; Michael R Hayden
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

5.  A daily glass of red wine associated with lifestyle changes independently improves blood lipids in patients with carotid arteriosclerosis: results from a randomized controlled trial.

Authors:  Dirk W Droste; Catalina Iliescu; Michel Vaillant; Manon Gantenbein; Nancy De Bremaeker; Charlotte Lieunard; Telma Velez; Michèle Meyer; Tessy Guth; Andrea Kuemmerle; Georges Gilson; Anna Chioti
Journal:  Nutr J       Date:  2013-11-15       Impact factor: 3.271

6.  Association between high-density lipoprotein cholesterol and type 2 diabetes mellitus among Chinese: the Beijing longitudinal study of aging.

Authors:  Xue Cao; Zhe Tang; Jie Zhang; Haibin Li; Manjot Singh; Fei Sun; Xiaochun Li; Changwei Li; Youxin Wang; Xiuhua Guo; Deqiang Zheng
Journal:  Lipids Health Dis       Date:  2021-07-17       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.